The Ebola outbreak in the Democratic Republic of Congo has become the fastest-spreading in the virus's history, with 2,003 confirmed cases and 796 deaths recorded in just two months since its declaration on 15 May. The World Health Organization now ranks it as the third-largest outbreak on record, noting that the previous major epidemic in the DRC took more than ten months to reach a comparable caseload. This acceleration, WHO officials in Geneva warn, means the virus is outpacing containment efforts despite a rapid scale-up of treatment and laboratory capacity.

The outbreak's velocity stems from a breakdown in traditional surveillance. More than 80 per cent of new cases in Ituri province are being detected outside known contact lists, indicating that transmission chains are being missed. Approximately two-thirds of deaths occur in communities, far from treatment centres, which allows the virus to spread undetected. Compounding the challenge, the outbreak is driven by the rare Bundibugyo species of Ebola, for which no approved vaccine or treatment exists. Health authorities in Kinshasa also face persistent insecurity: a treatment centre in Nyakunde was attacked overnight after a pregnant woman died, prompting the evacuation of humanitarian staff and reports that several Ebola patients fled the facility.

The response is now entering a critical experimental phase. Clinical trials for two potential treatments—the monoclonal antibody MBP134 and the antiviral remdesivir—began in Ituri on 2 July. A safety trial of the ChAdOx1 vaccine, led by the University of Oxford, commenced in early July, and a trial of the antiviral obeldesivir for post-exposure prophylaxis started the following day. These interventions remain in early-stage testing, with no efficacy data yet available. Meanwhile, the outbreak's cross-border dimension has triggered new travel policies. Viewed from Washington, the US government now requires American citizens returning from the DRC to spend 21 days in a third country before entering the United States. Seven asymptomatic American aid workers from the charity Samaritan's Purse are currently under quarantine at a US-built bioisolation facility in central Kenya—a site that has provoked local opposition and a court-ordered suspension of activities, though construction has continued.

The immediate milestone to watch is the funding response. The WHO and the Africa Centres for Disease Control have launched a joint plan that faces a shortfall of more than $400 million. Without additional resources, officials say, the capacity to strengthen surveillance, conduct safe burials, and manage clinical cases in the conflict-ridden east will remain strained. The next factual marker will be preliminary safety and immunogenicity data from the vaccine trial, expected in the coming months, which will determine whether a larger efficacy study can proceed.